Evidence map›Paper›PMID 35492815›Full record

ReviewJACC. CardioOncology2022

The Role of Cardioprotection in Cancer Therapy Cardiotoxicity:

Torbjørn Omland, Siri Lagethon Heck, Geeta Gulati

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. CardioOncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06005259 (Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity), which is not on this map. Cited by 98 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06005259 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)

TypeinterventionalSponsorUniversity of Sao PauloRan2023 to 2025Enrolled264ConditionsCardiotoxicity, Neoplasms, Chemotherapy Effect, Heart FailureArmsSpironolactone, Placebo
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Risk-guided cardioprotection in cardio-oncology.Nature cardiovascular research · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Torbjørn OmlandDepartment of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
Siri Lagethon HeckInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Geeta GulatiInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and targeted cancer therapies. Both general measures and specific pharmacologic cardioprotective interventions as well as imaging- and biomarker-based surveillance strategies to identify patients at high risk have been tested in randomized controlled trials to prevent or attenuate cancer therapy-related cardiotoxic effects. Although meta-analyses including early trials suggest an overall beneficial effect, there is substantial heterogeneity in results. Recent randomized controlled trials of neurohormonal inhibitors in patients receiving anthracyclines and/or human epidermal growth factor receptor 2-targeted therapies have shown a lower rate of cancer therapy-related cardiac dysfunction than previously reported and a modest or no sustained effect of the interventions. Data on preventive cardioprotective strategies for novel cancer drugs are lacking. Larger, prospective multicenter randomized clinical trials testing traditional and novel interventions are required to more accurately define the benefit of different cardioprotective strategies and to refine risk prediction and identify patients who are likely to benefit.

Indexed as

ACE, angiotensin-converting enzymeADT, androgen deprivation therapyanthracyclineARB, angiotensin receptor blockercardiomyopathyCMR, cardiovascular magnetic resonanceCTRCD, cancer therapy–related cardiac dysfunctionGLS, global longitudinal strainGnRH, gonadotropin-releasing hormoneHER2, human epidermal growth factor receptor 2HER2 therapyLVEF, left ventricular ejection fractionLV, left ventricularMRA, mineralocorticoid receptor antagonistpreventionRR, risk ratio

Identifiers

PMID35492815
PMCPMC9040117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.